Marpai Secures $12M via Convertible Preferred Stock at $1.00 Conversion Price, Led by Mitchell Companies

summarizeSummary

Marpai raised $12.1 million through a convertible preferred stock offering with a $1.00 conversion price—a steep discount to the current $2.23 share price. The deal includes an 8% dividend, board observer rights for the lead investor, and registration rights, providing essential capital but at highly dilutive terms.

check_boxKey Events · Financing and Capital Events · MRAI

• $12.1M Private Placement

  Marpai sold 12,100 shares of Series A Preferred Stock at $1,000 per share, raising gross proceeds of $12.1 million. The initial closing is expected on or about July 31, 2026.

• Deeply Discounted Conversion Price

  Each preferred share converts into Common Stock at $1.00 per share—a 55% discount to the current $2.23 stock price. At full conversion, the 12,100 preferred shares would become 12.1 million common shares, representing approximately 45% of the current 26.9 million outstanding shares, before accounting for the 8% dividend.

• 8% Dividend Payable in Common Stock

  Holders are entitled to an 8% cumulative dividend on the $1,000 stated value, payable in Common Stock upon conversion or a liquidity event, further increasing potential dilution.

• Lead Investor Gains Board Observer

  Mitchell Family Trust II, which invested $3 million, secured a two-year board observer seat for Steve Mitchell, Chairman of Mitchell Companies, enhancing its influence over company strategy.

auto_awesomeAnalysis · MRAI · Industrial Applications And Services

Marpai, a micro-cap healthcare services company carrying a going-concern warning and fresh off a debt restructuring, has closed a $12.1 million private placement of Series A Preferred Stock. The conversion price of $1.00 per share represents a steep discount to the current $2.23 stock price, and the 8% dividend is payable in common stock—both features that amplify dilution risk. The lead investor, Mitchell Family Trust II, gains a board observer seat, while purchasers receive registration rights, participation rights in future financings, and most-favored nation protection. Although the capital infusion is critical for extending the company's runway, the deeply discounted conversion price and dilutive structure pose substantial risk to existing shareholders. The filing finalizes terms of the deal first reported by Reuters on July 29, adding specifics that materially alter the investment thesis.